So far, China has made no official public threat about weaponizing its dominant position in this segment of the pharmaceutical industry. But Trump’s tariffs on the sector, if imposed, could worsen ...

SINGAPORE—China is racing toward economic self-sufficiency by weaning itself off American technology. But it has made a ...

China has leaped from fast follower to global pioneer in drug discovery and development. We believe that Chinese companies ...

The president’s proposed 25 percent tariffs on pharmaceutical imports will be catastrophic. There are other options to bring ...

For all the attention on U.S.-China AI competition, new studies point to China’s rapid rise in biotechnology, especially for ...

Mayur Maheshwari, CEO of UPSIDA, said the Bulk Drug Pharma Park would be important in reducing India's dependence on China ...

In this era of escalating trade tensions and geopolitical uncertainty, the U.S. cannot afford to cede another critical ...

China’s National Medical Products Administration (NMPA) has conditionally approved Zymeworks’ zanidatamab for biliary tract ...

Under the deal, announced on May 20, Pfizer gains the opportunity to develop and sell the SSGJ-707 drug in markets outside of ...

Instead of battling over tariffs, Washington and Beijing have turned to a potentially far more harmful strategy: flexing ...

So far, China has made no official public threat about weaponizing its dominant position in this segment of the pharmaceutical industry. But Trump’s tariffs on the sector, if imposed ...